The Merck Group (commonly known as Merck) is one of the oldest multinational chemical and pharmaceutical company globally, founded in 1668 by Friedrich Jacob Merck. Entire business of the group can be broadly divided into three categories: Healthcare, Life Science and Electronics. Headquartered in Darmstadt, Germany, Merck operates in 66 countries with more than 60,348 employees as of 2021. Merck has operations throughout Europe, Africa, Asia, Oceania, and the Americas. It has major research and development centres in Darmstadt, Boston, Tokyo, and Beijing, as well as other R&D units in Taiwan, France, Israel, South Korea, India, and the United Kingdom. Merck announced a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT) in June 2022. PAT is a critical enabler for real-time release and Bioprocessing 4.0, and is strongly encouraged by global regulatory authorities.
The USP of Merck lies in it being ranked under Top 10 largest pharma companies in the world. Merck’s mission is “to improve health and well-being and help people in low- and middle-income countries and underserved regions to lead better lives.”
Business Sector
Pharmaceuticals and Chemicals
Operating Geography
Germany, Europe, Global
Revenue
€ 22,232 million – FY ended 31st December 2022 (year-on-year growth of 12.9%)
€ 19,687 million – FY ended 31st December 2021
SWOT
SWOT Matrix for Merck
Strength
Weakness
Global leader in fertility drugs and treatment
Continued investments to expand capabilities and production
Consistently strong financial performance
Risk diversified business portfolio
Strong focus on R&D to introduce new product offerings
Strong Investment grade rating
Weak player in Latin America, middle east and Africa
Opportunity
Threat
Great potential to dominate future automotive and lighting display market
Accelerating demand of semiconductor materials
Growth in pharmaceutical industry due to Covid-19
Leveraging e-commerce and distribution platform
Growth due to CRISPR technology
Increasing relevance of emerging markets
Negative political and macroeconomic developments
Detailed SWOT Analysis of Merck
The detailed SWOT analysis for The Merck Group is presented below:
Strength
Global leader in fertility drugs and treatment: The fertility franchise of Merck, which dominates the global market for fertility medications and treatments, is a significant growth engine for its Biopharma division. The leading therapeutic within its fertility portfolio, GONAL-f®2, has assisted in the birth of more than 4 million children to date. With the introduction of its Gonal-f® (follitropin alfa) 150 IU pen, Merck provided patients with additional assistance during the Covid-19 pandemic in order to advance their treatment at home. It was introduced in Portugal, Finland, and Poland in 2021. The Gonal-f® pen's user-friendliness and patient-friendliness were highlighted in a number of studies involving patients seeking fertility treatment and nurses. The first product with recombinant follicle-stimulating hormone (r-hFSH) and recombinant luteinizing hormone (r-hLH) combined in a ready-to-use liquid form is Merck's Pergoveris® pen, which does not require mixing. As a result, it is an effective treatment for women who have severe FSH and LH deficiency. GONAL-f® 150 IU pen was released in various European and APAC (Asia Pacific) nations in 2022, including France, the Baltic countries, Indonesia, Malaysia, and Singapore. Further releases are planned for 2023 in Europe, APAC, and MEAR (Middle East, Africa, Turkey, Russia, and the Commonwealth of Independent States), as well as 2024 in Japan.
Continued investments to expand capabilities and production: In pursuit of their commitment to accelerate the advancement and accessibility of forthcoming medical solutions for patients in need, Merck Group commemorated the laying of the foundation stones for two significant facilities in July and September at their Darmstadt campus. These developments, scheduled to reach full operational status by the conclusion of 2025, constitute integral components of a comprehensive €1.5 billion investment initiative revealed in March. The Translational Science Center, a venture amounting to €200 million, will encompass a sprawling 30,000 square meter establishment that seamlessly amalgamates laboratories, a lecture hall, and office spaces. This collaborative setting will facilitate interdisciplinary cooperation among scientists, fostering innovative research spanning the gamut from disease biomarker identification to the formulation of precisely targeted therapeutic interventions. Concurrently, the Launch and Technology Center, backed by an investment of €160 million, will provide an expansive 13,900 m2 expanse. Dovetailing cutting-edge technology with human-centered design, this facility will effectively bridge the gap between research and commercial manufacturing endeavours. Its primary objective is to ensure punctual and top-tier availability of Merck Group's upcoming pharmaceuticals, facilitating seamless transitions to clinical trials, global launches, and commercial distribution, all while adhering to stipulated standards of quality and quantity.
The remaining points in this section are available in the 'Complete Report' on purchase.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
This section is available only in the 'Complete Report' on purchase.
Threat
This section is available only in the 'Complete Report' on purchase.
PESTLE
PESTLE Matrix for Merck
Political
Economic
Policies regarding the health insurance in the Germany
Self-governing body to develop healthcare frameworks throughout the country
Right to health policies
Slowdown in European Economy
Asia-Pacific region to present significant growth opportunities
Social
Technological
Increased awareness towards heath
Privatization of healthcare leading to higher useof technologies
Use of tech. to reduce time to market for drugs
Legal
ENVIRONMENTAL
Highly standardized markets with stringent regulations
Involvement in various lawsuits
Working towards energy conservation
Design for sustainability’ program to address adverse environmental impacts
Detailed PESTLE Analysis of Merck
The detailed PESTLE analysis for The Merck Group is presented below:
POLITICAL
Policies regarding the health insurance in the Germany: Germany, the major operating geography of Merck has one of the densest healthcare providing structures of the world. The utilization of this system is also the highest in the world. A statutory healthcare insurance is mandatory for all the citizens of the Germany, and anyone earning above a certain level can choose from a huge set of 124 private health insurance companies. The mandatory insurance will cause a lot more people to go freely for health check-ups and several new diagnoses may occur, which without the policy would not have happened. A free approach of the people who are readily looking to free their bodies even of the slightest of the disease will cause more consumption of medicines. This may boost the prospects of the local pharma companies such as Merck who may come out with generic variants of several drugs.
The remaining points in this section are available in the 'Complete Report' on purchase.
ECONOMIC
This section is available only in the 'Complete Report' on purchase.
SOCIAL
This section is available only in the 'Complete Report' on purchase.
TECHNOLOGICAL
This section is available only in the 'Complete Report' on purchase.
LEGAL
This section is available only in the 'Complete Report' on purchase.
ENVIRONMENTAL
This section is available only in the 'Complete Report' on purchase.
Table of Contents
Company Overview
1.1 About the Company
1.2 Business Sector
1.3 Operating Geography
1.4 Revenue
SWOT Analysis
2.1 SWOT Table/ SWOT Matrix
2.2 SWOT Overview
2.3 Detailed SWOT Analysis
2.4 Strength, Weakness, Opportunity and Threat
PESTLE Analysis
3.1 PESTLE Table/ PESTLE Matrix
3.2 PESTLE Overview
3.3 Detailed PESTLE Analysis
3.4 Political, Economic, Social, Technological, Legal and Environmental
You can use the following in your reference section to
give credit to the source. For different referencing
styles and detailed guidelines, please
click here
Merck Group and Palantir Forge Ahead with Open Collaboration: https://analyticsindiamag.com/merck-group-and-palantir-forge-ahead-with-open-collaboration/
Germany Health System Overview: https://healthsystemsfacts.org/national-health-systems/bismarck-model/germany/germany-health-system-overview/
The detailed complete set of references is available on request in the 'Complete report' on purchase.
The Merck Group SWOT and PESTLE analysis has been conducted and reviewed by senior analysts from Barakaat Consulting.
Copyright of The Merck Group SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.
The reports published by SWOT & PESTLE.com are created under a stringent life cycle which undergoes data validation checks and quality surveillance at each of the stages of data procurement, identification, selection, processing, extraction and analysis. Earnest efforts are made to capture and validate the quality and preciseness of data. Our analysts by and large use the following sources to put together valuable analytical research reports:
Company annual reports and SEC filings (10-K, 20-F, 10-Q etc)
Company official portal
Investors presentations
Research reports of key industry players/competitors
Historical data
Data from government sources
Media releases which include journals, published literature, press releases, market information that cover industry news, country news, and customer intentions.
An aggregation of the experiences, expertise and insights of our analysts who go through volumes of data to extract meaningful information.
Why Choose Us?
Other Analysis
Related Report
Recently Viewed
Delivery Within * 1 Hour
This report contains the table contents only. In case you
need the complete report please purchase using the buy
options displayed.
This is the sample complete report which will give you a
glimpse of what your complete report will cover after
purchase.
Get the report (PDF) delivered to your email within minutes.
** Get the report (PDF) sent to your email within
minutes
The illustrative sample reports are shared in order to give
you an idea of what the SWOT & PESTLE Report for The Merck Group will cover
after purchase. We invest deep in order to bring you
insightful research which can add tangible value to your
business or academic goals, at affordable pricing.
Value Subscription Plans
Subcription Plans start with as low as $53
Custom Research Reports
Are you looking for a report which is customised to
align with your business needs?
Our custom research services provide incisive
competitive acuity you need to dig In to the right data
and provide actionable insights decisions for your
business.
Our experienced analysts and
consultants will ensure comprehensive coverage and
tailor it to best fit your needs.
Please note that custom research reports have a
delivery period anywhere between
1 to 5 business days.
Delivery Within * 1 Hour
The Merck Group SWOT & PESTLE
In case you want this report emailed straight into your email
inbox, kindly share your details below. Please note that you agree
to receive email updates from us on our new reports and solutions.
